These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

778 related articles for article (PubMed ID: 19485791)

  • 1. Doripenem: position in clinical practice.
    Dedhia HV; McKnight R
    Expert Rev Anti Infect Ther; 2009 Jun; 7(5):507-14. PubMed ID: 19485791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
    Matthews SJ; Lancaster JW
    Clin Ther; 2009 Jan; 31(1):42-63. PubMed ID: 19243706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
    Jones RN; Huynh HK; Biedenbach DJ; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2004 Jul; 54(1):144-54. PubMed ID: 15190031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doripenem: a new carbapenem in the treatment of nosocomial infection.
    Mandell L
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S1-3. PubMed ID: 19619016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.
    Kiratisin P; Chongthaleong A; Tan TY; Lagamayo E; Roberts S; Garcia J; Davies T
    Int J Antimicrob Agents; 2012 Apr; 39(4):311-6. PubMed ID: 22386743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of doripenem.
    Sahm D
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S11-6. PubMed ID: 19619017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbapenems: a potent class of antibiotics.
    Nicolau DP
    Expert Opin Pharmacother; 2008 Jan; 9(1):23-37. PubMed ID: 18076336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
    Castanheira M; Jones RN; Livermore DM
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):426-33. PubMed ID: 19249180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of a novel carbapenem, doripenem, against anaerobic pathogens.
    Goldstein EJ; Citron DM
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):447-54. PubMed ID: 19249176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of doripenem tested against prevalent Gram-positive pathogens: results from a global surveillance study (2003-2007).
    Fritsche TR; Sader HS; Stillwell MG; Jones RN
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):440-6. PubMed ID: 19302928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
    Lucasti C; Jasovich A; Umeh O; Jiang J; Kaniga K; Friedland I
    Clin Ther; 2008 May; 30(5):868-83. PubMed ID: 18555934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of ertapenem: review of recent studies.
    Wexler HM
    J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
    Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 May; 52(1):71-4. PubMed ID: 15878447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens.
    Poulakou G; Giamarellou H
    Expert Opin Investig Drugs; 2008 May; 17(5):749-71. PubMed ID: 18447600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimicrobial resistance among and therapeutic options against gram-negative pathogens.
    Rahal JJ
    Clin Infect Dis; 2009 Aug; 49 Suppl 1():S4-S10. PubMed ID: 19619021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.
    Snydman DR; Jacobus NV; McDermott LA
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4492-6. PubMed ID: 18838581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
    Fritsche TR; Stilwell MG; Jones RN
    Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Available carbapenems: Properties and differences].
    Martínez MJ; García MI; Sánchez EG; Sánchez JE
    Enferm Infecc Microbiol Clin; 2010 Sep; 28 Suppl 2():53-64. PubMed ID: 21130931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation.
    Kongnakorn T; Mwamburi M; Merchant S; Akhras K; Caro JJ; Nathwani D
    Curr Med Res Opin; 2010 Jan; 26(1):17-24. PubMed ID: 19895363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbapenems in the USA: focus on doripenem.
    Lister PD
    Expert Rev Anti Infect Ther; 2007 Oct; 5(5):793-809. PubMed ID: 17914914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.